Amgen Inc. $AMGN Stock Position Decreased by Eurizon Capital SGR S.p.A.

Eurizon Capital SGR S.p.A. cut its position in Amgen Inc. (NASDAQ:AMGN) by 8.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 248,243 shares of the medical research company’s stock after selling 21,790 shares during the quarter. Eurizon Capital SGR S.p.A.’s holdings in Amgen were worth $104,680,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of AMGN. Wellington Altus USA Inc. increased its stake in shares of Amgen by 72.3% in the second quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock worth $28,000 after purchasing an additional 34 shares during the period. Quest 10 Wealth Builders Inc. boosted its stake in Amgen by 220.0% during the 3rd quarter. Quest 10 Wealth Builders Inc. now owns 80 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 55 shares during the period. Nvwm LLC boosted its stake in Amgen by 412.5% during the 3rd quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 66 shares during the period. Security National Bank of Sioux City Iowa IA bought a new stake in Amgen during the 2nd quarter valued at approximately $36,000. Finally, PFS Partners LLC grew its holdings in Amgen by 95.5% in the 3rd quarter. PFS Partners LLC now owns 86 shares of the medical research company’s stock valued at $36,000 after buying an additional 42 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Recent Amgen Headlines

Here are a few of the latest headlines about AMGN:

• Positive Sentiment: Dazodalibep met the primary endpoint in the 648-patient OASIZ-301 trial, with both dosing regimens showing statistically significant improvement in systemic disease activity. Amgen also reported meaningful improvement in patient-reported symptoms. Sjögren’s currently has no approved treatments, giving the results potential commercial significance if confirmed and approved. Reuters article
• Positive Sentiment: Jefferies analysts said, with caveats about cross-trial comparisons, dazodalibep appears more effective than Novartis’ competing investigational drug ianalumab. That could strengthen Amgen’s competitive position, though it is not a direct head-to-head comparison. Clinical Trials Arena article
• Positive Sentiment: Argus raised its price target to $515 from $460 and maintained a Buy rating, signaling increased analyst optimism. Separately, ETFs bought a net $66.8 million of AMGN shares on Nov. 10, indicating institutional demand. Yahoo Finance article

Amgen Price Performance

Shares of Amgen stock opened at $467.06 on Friday. The company has a debt-to-equity ratio of 3.60, a quick ratio of 1.20 and a current ratio of 1.48. The firm’s 50-day simple moving average is $424.87 and its 200-day simple moving average is $380.60. Amgen Inc. has a twelve month low of $312.39 and a twelve month high of $483.99. The firm has a market cap of $252.64 billion, a P/E ratio of 27.09, a price-to-earnings-growth ratio of 3.27 and a beta of 0.43.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. The business had revenue of $10.37 billion for the quarter, compared to analysts’ expectations of $10.07 billion. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The firm’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.64 earnings per share. As a group, research analysts expect that Amgen Inc. will post 23.33 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Friday, November 20th. Amgen’s dividend payout ratio is currently 58.47%.

Analyst Upgrades and Downgrades

Several research analysts have commented on AMGN shares. Piper Sandler lifted their price target on Amgen from $427.00 to $457.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. Morgan Stanley increased their price objective on Amgen from $359.00 to $410.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 4th. Robert W. Baird raised their price objective on shares of Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 5th. Royal Bank Of Canada boosted their target price on shares of Amgen from $430.00 to $470.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 4th. Finally, Guggenheim boosted their target price on shares of Amgen from $378.00 to $435.00 and gave the stock a “neutral” rating in a research report on Thursday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, Amgen has an average rating of “Hold” and an average price target of $424.66.

Amgen Company Profile

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.